Tolga Tanguler Sells 1,959 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president owned 31,769 shares in the company, valued at $9,850,931.52. The trade was a 5.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tolga Tanguler also recently made the following trade(s):

• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Trading Up 0.0%

NASDAQ ALNY opened at $332.68 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock’s fifty day moving average price is $369.58 and its 200-day moving average price is $423.61. The stock has a market cap of $44.12 billion, a P/E ratio of 194.55 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the firm earned ($0.65) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $27,000. Finally, Ameriflex Group Inc. bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $32,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday. Leerink Partners decreased their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Raymond James Financial restated an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Finally, Barclays started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective on the stock. Twenty-two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” on ALNY and set a $510 price target, implying substantial upside vs. current levels — a strong analyst vote of confidence for growth expectations. Read More.
• Positive Sentiment: Canaccord Genuity raised its price target from $415 to $429 and kept a “buy” rating, supporting near‑term buyer interest. Read More.
• Positive Sentiment: Freedom Capital Markets upgraded ALNY (reported via MSN), and a Motley Fool piece highlighted an influential pundit upgrade that helped lift momentum earlier in the week — both items can attract more buying. Read More. · Read More.
• Neutral Sentiment: Valuation commentary: a Yahoo Finance piece framed Alnylam’s valuation as mixed — models show bullish fair‑value scenarios but recent returns are uneven; useful context for longer‑term investors rather than an immediate catalyst. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feed show zero/NaN values and a 0.0 days‑to‑cover metric — this appears to be a data/reporting artifact and should be treated as non‑actionable until exchange‑confirmed. (No reliable link available.)
• Negative Sentiment: Multiple insider sales were disclosed this week that could pressure sentiment: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold shares in mid‑thousands at ~$310–332 — large insider liquidity events can be perceived negatively by investors. Read More. · Read More.
• Negative Sentiment: Some sell‑side pressure: Chardan trimmed a price target to $425 and other brokers (e.g., Morgan Stanley, Wells Fargo) have lowered targets or applied neutral/equal‑weight ratings earlier — mixed analyst views add volatility risk vs. unanimous buy signals. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.